Cost-utility analysis of genomic profiling in early breast cancer in Colombia

Rojas, Leonardo; Rojas-Reyes, María X.; Rosselli, Diego; Ariza, Juan Guillermo; Ruiz-Patiño, Alejandro; Cardona, Andrés F.

doi:10.1186/s12962-023-00449-5

Cost Effectiveness and Resource Allocation

Table 2 Variables, values, and parameters used for DSA and PSA

From: Cost-utility analysis of genomic profiling in early breast cancer in Colombia

Variable	Base case	Range DSA		Distribution and parameters PSA			References
Variable	Base case	Lower	Higher	Distribution	⍺	β	References
Chemotherapy
DRFS 5 years	0.939	0.925	0.950	Log-normal	− 0.06	0.01	Database NCT00310180
OS 5 years	0.966	0.955	0.974	Log-normal	− 0.03	0.01
Chemotherapy
DRFS 5 years	0.939	0.925	0.950	Log-normal	− 0.06	0.01	Database NCT00310180
OS 5 years	0.966	0.955	0.974	Log-normal	− 0.03	0.01
ODX high risk
DRFS 5 years	0.914	0.895	0.930	Log-normal	− 0.09	0.01	Database NCT00310180
OS 5 years	0.957	0.943	0.968	Log-normal	− 0.04	0.01
ODX low risk
DRFS 5 years	0.972	0.963	0.979	Log-normal	− 0.03	0.00
OS 5 years	0.974	0.965	0.981	Log-normal	− 0.03	0.00	Database NCT00310180
ODX high risk
DRFS 5 years	0.914	0.895	0.930	Log-normal	− 0.09	0.01
OS 5 years	0.957	0.943	0.968	Log-normal	− 0.04	0.01	Database NCT00310180
ODX low risk
DRFS 5 years	0.972	0.963	0.979	Log-normal	− 0.03	0.00
OS 5 years	0.974	0.965	0.981	Log-normal	− 0.03	0.00
MMP high risk
DRFS 5 years	0.909	0.880	0.932	Log-normal	− 0.10	0.01	[19]
OS 5 years	0.955	0.934	0.969	Log-normal	− 0.05	0.01
MMP low risk
DRFS 5 years	0.949	0.928	0.963	Log-normal	− 0.05	0.01	[19]
OS 5 years	0.970	0.953	0.981	Log-normal	− 0.03	0.01
Cost
ODX	$3551	$2841	$4261	Gamma	96.4	362.36	Provider
MPT	$3551	$2841	$4261	Gamma	96.4	362.36	Provider
Rem.1^st year^a	$109.4	$76	$150	Gamma	33.84	18.80	[31], [32]
Rem. ≥ 2^nd year^a	$53.21	$32	$83	Gamma	16.58	13.07	[31], [32]
Adjuvant chemotherapy^a	$464.38	$243	$807	Gamma	10.44	148.01	[31], [32]
Recurrence^a
Palliative care^a	$4587.45	$4248	$4935	Gamma	684.17	180.64	[31], [32]
Adverse event^a	$248.95	$213	$300	Gamma	125.06	22.93	[31], [32]
Utility^a
Recurrence-free survival	0.9	0.85	0.95	Beta	7.50	92.50	[27, 28]
Recurrence
Adjuvant chemotherapy	0.55	0.44	0.66	Beta	2.42	97.58	[27,28,29]
	0.74	0.59	0.89	Beta	6.17	93.83	[27]
Adverse event	0.07	0.02	0.08	-	–	–	[35], [36]

^a monthly
DSA deterministic sensitivity analysis, PSA probabilistic sensitivity analysis, ⍺ y β probabilistic distribution parameters, DRFS distant recurrence-free survival OS overall survival, ODX Oncotype DX, MMP Mammaprint, Rem remission

Back to article page

ISSN: 1478-7547

Contact us

General enquiries: journalsubmissions@springernature.com